Trials / Completed
CompletedNCT00691964
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 347 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABT-874 | SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8 |
| BIOLOGICAL | etanercept | SQ injection 50 mg BIW |
| DRUG | placebo | SQ placebo injections for ABT-874 and etanercept |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-06-06
- Last updated
- 2013-01-21
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00691964. Inclusion in this directory is not an endorsement.